Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Appili Therapeutics (TSX: APLI; OTCPink: APLIF) announced that President and CEO Don Cilla will participate in Aditxt Weekly Update on April 4, 2025, alongside Aditxt CEO Amro Albanna. The discussion will focus on:
- The company's ongoing going-private transaction with Aditxt
- $117 million in new federal funding applications
- The growing threat of emerging infectious diseases
- Appili's near-to-market portfolio addressing unmet patient needs
The company highlighted its success in securing non-dilutive funding, including $33.2 million in prior government awards. The event will include a Q&A session, with Appili planning to participate in additional Aditxt Weekly Updates throughout the year.
Appili Therapeutics (TSX: APLI; OTCPink: APLIF) ha annunciato che il Presidente e CEO Don Cilla parteciperà all'Aditxt Weekly Update il 4 aprile 2025, insieme al CEO di Aditxt Amro Albanna. La discussione si concentrerà su:
- La transazione in corso per il passaggio a società privata con Aditxt
- Domande di finanziamento federale per un totale di $117 milioni
- La crescente minaccia delle malattie infettive emergenti
- Il portafoglio di Appili vicino al mercato che affronta le esigenze insoddisfatte dei pazienti
L'azienda ha evidenziato il suo successo nel garantire finanziamenti non diluitivi, inclusi $33,2 milioni in premi governativi precedenti. L'evento includerà una sessione di domande e risposte, con Appili che prevede di partecipare ad ulteriori Aditxt Weekly Updates nel corso dell'anno.
Appili Therapeutics (TSX: APLI; OTCPink: APLIF) anunció que el Presidente y CEO Don Cilla participará en el Aditxt Weekly Update el 4 de abril de 2025, junto al CEO de Aditxt Amro Albanna. La discusión se centrará en:
- La transacción en curso para convertirse en una empresa privada con Aditxt
- Solicitudes de financiamiento federal por un total de $117 millones
- La creciente amenaza de enfermedades infecciosas emergentes
- El portafolio de Appili cercano al mercado que aborda las necesidades no satisfechas de los pacientes
La empresa destacó su éxito en asegurar financiamiento no dilutivo, incluyendo $33.2 millones en premios gubernamentales anteriores. El evento incluirá una sesión de preguntas y respuestas, con Appili planeando participar en actualizaciones semanales adicionales de Aditxt a lo largo del año.
Appili Therapeutics (TSX: APLI; OTCPink: APLIF)는 2025년 4월 4일 Aditxt Weekly Update에 참여할 것이라고 발표했습니다. 이 행사에는 Aditxt의 CEO인 Amro Albanna와 함께할 예정입니다. 논의의 주요 내용은 다음과 같습니다:
- Aditxt와의 비상장 거래 진행 상황
- 1억 1천7백만 달러의 새로운 연방 자금 신청
- 신흥 감염병의 증가하는 위협
- 환자의 미충족 요구를 해결하는 Appili의 시장 진입 포트폴리오
회사는 3천3백2십만 달러의 정부 보조금을 포함하여 비희석적 자금을 확보한 성공을 강조했습니다. 이번 행사에는 질문과 답변 세션이 포함되며, Appili는 올해 동안 추가적인 Aditxt Weekly Update에도 참여할 계획입니다.
Appili Therapeutics (TSX: APLI; OTCPink: APLIF) a annoncé que le Président et CEO Don Cilla participera à la Aditxt Weekly Update le 4 avril 2025, aux côtés du CEO d'Aditxt Amro Albanna. La discussion se concentrera sur :
- La transaction en cours pour le passage à une société privée avec Aditxt
- Des demandes de financement fédéral s'élevant à 117 millions de dollars
- La menace croissante des maladies infectieuses émergentes
- Le portefeuille d'Appili proche du marché répondant aux besoins non satisfaits des patients
L'entreprise a souligné son succès dans l'obtention de financements non dilutifs, y compris 33,2 millions de dollars en prix gouvernementaux antérieurs. L'événement comprendra une session de questions-réponses, Appili prévoyant de participer à d'autres mises à jour hebdomadaires d'Aditxt tout au long de l'année.
Appili Therapeutics (TSX: APLI; OTCPink: APLIF) gab bekannt, dass Präsident und CEO Don Cilla am Aditxt Weekly Update am 4. April 2025 teilnehmen wird, zusammen mit Aditxt-CEO Amro Albanna. Die Diskussion wird sich auf Folgendes konzentrieren:
- Die laufende Umwandlung des Unternehmens in eine Privatgesellschaft mit Aditxt
- Neue Anträge auf Bundesfinanzierung in Höhe von 117 Millionen Dollar
- Die wachsende Bedrohung durch aufkommende Infektionskrankheiten
- Das fast marktfähige Portfolio von Appili, das unbefriedigte Patientenbedürfnisse anspricht
Das Unternehmen hob seinen Erfolg bei der Sicherstellung von nicht verwässernden Finanzierungen hervor, einschließlich 33,2 Millionen Dollar an früheren staatlichen Auszeichnungen. Die Veranstaltung wird eine Frage- und Antwortsitzung umfassen, und Appili plant, im Laufe des Jahres an weiteren Aditxt Weekly Updates teilzunehmen.
- Substantial potential funding with $117 million in new federal applications submitted
- Strong track record of securing non-dilutive funding with $33.2 million in prior government awards
- Going-private transaction may impact current shareholders' ownership structure
Event exploring the escalating threat of emerging infectious diseases
Discussion covering going-private transaction with Aditxt, strategic growth partner
HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company’s recent operational highlights, including
Dr. Cilla will join Aditxt to explore the escalating threat of emerging infectious diseases and highlight the vital role of strategic partnerships in developing innovative treatments and improving global public health. The Aditxt Weekly Update will also provide insights into Appili’s diverse near-to-market portfolio, designed to address critical unmet patient needs.
Additionally, the discussion will highlight Appili’s proven track record in securing non-dilutive funding, showcasing
Participants are encouraged to register in advance by clicking here. The event will also include a Q&A session, with questions welcomed at info@appilitherapeutics.com.
Appili will join additional Aditxt Weekly Updates throughout the year.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Forward Looking Statements
This news release contains “forward-looking statements”, including with respect to the potential for partnered projects to be developed, the potential that Appili will receive government awards and / or contracts related to its proposal submissions, the availability of future funding under the USAFA cooperative agreement, the Company’s development plan with respect to ATI-1701 and the expected timing and process to complete the Transaction. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in (i) the annual information form of the Company dated June 25, 2024, (ii) the Circular, and (iii) and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
Media Contact:
Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: Info@AppiliTherapeutics.com
FAQ
What is the total value of Appili Therapeutics' (APLIF) new federal funding applications?
How much government funding has APLIF previously secured?
When is Appili Therapeutics (APLIF) CEO participating in the Aditxt Weekly Update?
What is the status of APLIF's going-private transaction with Aditxt?
